A billion-dollar pharmaceutical was being targeted by a network of individuals and groups that appeared to be independent and disparate entities. We were able to trace the coordinated and specific hostile actions as being orchestrated and financed by a single organization with the objective or pushing the client’s product out of the marketplace and weakening their share price.
